TOMDF
TODOS MED LTD ORD
Latest price
As of Oct 26, 2026, 9:31 AM EDT · Market data by Massive
Market cap
—
Volume
30K
Previous close
$0.0000
Day range
$0.0000 – $0.0000
Listed
—
Coverage
87 articles
Price performance
Recent trading
Newsroom
Latest TOMDF coverage
Todos Medical Announces Insolvency Proceedings in Israel
[ad_1] NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, Israel – (NewMediaWire) – December 22, 2023 – Todos Medical, Ltd. (OTCQB: TOMDF), an innovative healthcare solutions company, today announced that a trustee was appointed (the “Trustee”) with respect to an insolvency order that was issued with respect to the Company in Israel related to a re
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
[ad_1] NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL – (NewMediaWire) – September 26, 2023 – Todos Medical, Ltd. (OTCQB: TOMDF), an innovative healthcare solutions company, today provided a corporate update to its stakeholders centered on the Company’s efforts to retool and focus primarily on addressing the Long COVID epidemic that is a
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid and Tollovir Ingredients
[ad_1] Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad’s lifelong work NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL – (NewMediaWire) – August 30, 2023 – Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and related solutions company, today announced that the United States Paten
Todos Medical Supports Long COVID Awareness Day
[ad_1] NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL – (NewMediaWire) – March 15, 2023 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced its support for International Long COVID Awareness Day. Todos Medical is fully aligned with the Long COVID community and its effo
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
[ad_1] Moratorium Goes Into Effect After Market Close on March 13, 2023 NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL – (NewMediaWire) – March 13, 2023 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the Company has entered into a new agreement with holders of its
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – February 14, 2023 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based Avian Influenza A (H5N1, bird flu) h
Todos Medical to Attend World Antiviral Congress
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 22, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that company representatives will attend World Antiviral Congress 2022. Event Details: World Antiviral Congress 2022 Date: 28th of November, 2
Todos Medical Announces Third Quarter 2022 Financial Results
[ad_1] § 89% increase in Q3/2022 quarterly revenues as compared with Q3/2021 § Earnings and business update call to be held at 9:30am ET on November 15, 2022 New York, NY and Tel Aviv, Israel – (NewMediaWire) – November 15, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announ
Todos Medical Terminates Tollovid Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 10, 2022 – via NewMediaWire —Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has terminated the Tollovid™ products license and distribution agreement it had with T-Cell Protect Hellas S.
Todos Medical Announces BioFuture NYC 2022 Presentation
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 4, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be making a corporate presentation and providing a corporate update to the investment communit
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – October 14, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified clinical laboratory Provista Diagnostics has filed an Emergency Use Authorization (EUA) application with the US Foo
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 30, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has received two Notices of Allowance from the United States Patent & Trademark Office (USPTO) for patent applications covering the C
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 27, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. received a Notice of Allowance issued by the USPTO for the Company’s proprietary SARS-C
Todos Medical Partner NLC Pharma Assigns IP for Tollovir, Tollovid, and TolloTest into JV 3CL Pharma
[ad_1] • 3CL Pharma preparing crowdfunding to fund Tollovir EUA filing in hospitalized COVID patients and Tollovir, Tollovid and TolloTest clinical development for Long COVID • Funding also to be used to support US national marketing campaign for Tollovid sales New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 12, 2022 R
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 9, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released the Nasdaq MarketSite interview between Moneta Advisory Group’s Managing Partner Marc LoPresti and CEO Gerald Commissiong, discussing the impac
Todos Medical Announces Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
[ad_1] Company also retains B2i Digital to enhance engagement with the investor community New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 2, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a brand ambassador agreement wit
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – August 23, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has initiated a MonkeyPox diagnostic case study series e
Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET
[ad_1] Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in Long COVID Now Complete Launch of New Suite of PCR Tests at Provista Underway, Including MonkeyPox Saliva Testing NEW YORK, NY, and TEL AVIV – (NewMediaWire) – August 22, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – August 19, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of results from the first 100-participant study from
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
[ad_1] RTHM collaborating on Tollovid™ 3CL inhibitor immune support supplement case studies Tollovid biomarker data to support potential structure-function claims in Long COVID New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – August 5, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related soluti
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid Treatment Followed by Tollovid Dietary Supplementation
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – July 22, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of case study #8 entitled “A Case Review: Effects of 3
Todos Medical Reports Case Study #7 in Acute and Long COVID
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – July 12, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the outcome from a sponsored case study overseen by Dr. Lee Morgentaler in concert
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
[ad_1] § Biomarker data correlates with clinical data announced in January 2022 § 46 patient open label extension being opened to support US FDA EUA application New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – June 30, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid Market Research Study in Acute and Long COVID
[ad_1] 83% of Respondents With Acute COVID Were Satisfied 68% of Respondents With Long COVID Were Satisfied NEW YORK, NY, and TEL AVIV, ISRAEL – (NewMediaWire) – June 23, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced preliminary data from its majority-owned join
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – June 21, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has retained Moneta Advisory Partners (“Moneta”) to act as strategic advisors for the Company’s planned listing on a national exchange and
Todos Medical Reports Day 45 Update for Case Study #6
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – June 10, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 45 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease c
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – June 7, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 28 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease cl
Todos Medical to Present at The LD Micro Conference
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – June 6, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical President and CEO Gerald Commissiong will present at the LD Micro Conference on June 8, 2022. Event: LD Micro Conference Date:
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer's Blood Test Clinical Validation Trial vs. Amyloid PET
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – June 3, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its academic partner, Dr. Thomas Arendt at Leipzig University, has completed full enrollment for 2nd cohort (confirmatory) for the ongoing cli
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – May 27, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that majority-owned subsidiary 3CL Pharma will present final data from the phase 2 clinical trial of Tollovir™ in the treatment of hospitalized (se
Todos Medical Releases Corporate Update
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – May 27, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released a corporate update from CEO Gerald Commissiong on the Company’s CLIA/CAP-certified lab Provista Diagnostics, an update on the Company’s 3CL Pharma m
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – May 06, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 14 update. The update is from an ongoing 30-day case study by Dr. Lee Morgentale
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Max Strength including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
[ad_1] · 5-day and 30-day dosing regimen for 60-pill bottle allows for both support (5-day dosing) to reduce 3CL protease levels and to maintain (30-day dosing) low 3CL protease levels New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – May 2, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and relat
Todos Medical to Present at the Emerging Growth Conference
[ad_1] – Wednesday, April 27, 2022 at 10:00am – 10:45am EST – New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – April 25, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical President and CEO Gerald Commissiong will present at the
UPDATE: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – April 1, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided corporate updates. “2021 was a strong year for Todos Me
Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – April 1, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided corporate updates. “2021 was a strong year for Todos Me
Todos Medical to Present at the Proactive One2One Virtual Forum
[ad_1] – Thursday, March 17, 2022 at 2:00 PM – 2:30 PM ET – NEW YORK, NY and Tel Aviv, ISRAEL – (NewMediaWire) – March 17, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical President CEO Gerald Commissiong will present at the Proactive
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir(TM) in the Treatment of Hospitalized COVID-19 Patients
[ad_1] § Phase 2 Study NLC-V-01 closed early after interim data analysis due to positive clinical efficacy § Primary endpoint of time to clinical improvement reached with average reduction of 2.7 days in the Tollovir group vs. the placebo group § 0% COVID-related deaths in Tollovir™ group vs. 22% COVID-related deaths in placebo group § ...
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
[ad_1] “COVID Testing: What Needs to Happen Now to Turn the Corner in 2022” CEO blog released New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – January 10, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will appear
Todos Medical CEO Provides Letter to Shareholders
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – January 5, 2022 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced that its President & CEO Gerald Commissiong today issued a letter to shareholders outlining the Company progresses towards a natio
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
[ad_1] § cPass neutralizing antibody testing seeing increasing demand, questions of infection-acquired immunity, vaccine-acquired immunity and booster shot durability emerge § The Company also entered into a new laboratory services agreement with a New Jersey-based physician practice for COVID PCR testing and cPass neutralizing antibody testing New York, N
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
[ad_1] § Provista completed validation for fingerprick At-Home sample collection of blood for the cPass neutralizing antibody test New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 22, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its highly a
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir(TM) Phase 2 & COVID Testing
[ad_1] CEO Gerald Commissiong is also scheduled to appear on BNC at 1:50PM EST to discuss the authorization of Pfizer’s COVID antiviral drug & Tollovir™ Phase 2 for hospitalized COVID New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 23, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related
Todos Medical Announces "Test & Tollovid(R)" Holiday Package for Atlanta Area at Provista Diagnostics
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 17, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab has launched the “Test & Tollovid®” Holiday Package for the Atlanta area. The Holiday Package is priced at $32
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 10, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical will be interviewed live on Benzinga’s All Access Conference held on December 14, 2021 at 10:20 AM Eastern Standard Time. T
Todos Medical to Present at Upcoming Emerging Growth Conference
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 6, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical will be presenting at the upcoming Emerging Growth Conference to be held on December 8, 2021. The follow
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 01, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that the management team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief Exec
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
[ad_1] Provista to also utilize Osang’s High-Capacity Reflex Variant PCR Detection Kit that has been confirmed to identify the Omicron variant New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 30, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has
Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
[ad_1] · The agreement calls for a minimum of 500,000 bottles in sales over 18 months · T-Cell Protect to invest 1 million euros in Todos to support development of Tollovir, the Company’s 3CL Protease Inhibiting Antiviral Drug Candidate New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 24, 202
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
[ad_1] Enrollment now paused in the randomized, double blind, placebo controlled clinical trial in severe and critical hospitalized COVID-19 patients to complete interim analysis Data from the interim analysis expected in the end of 4th Quarter of 2021 Jules Mitchel, PhD, appointed as strategic advisor to assist with the interim analysis New York, NY, and .
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
[ad_1] · Reauthorization of EUA expands beyond initial qualitative detection claim · CEO to appear on Cheddar News at 6:10pm tonight, November 17th, 2021 New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 17, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and relate
Update: Todos Medical Reports Third Quarter 2021 Business and Financial Results
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 16, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the third quarter ended September 30, 2021. Corporate Highlights Integration of COVID-19 PCR automat
Todos Medical Reports Third Quarter 2021 Business and Financial Results
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 15, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the third quarter ended September 30, 2021. Corporate Highlights Integration of COVID-19 PCR automati
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
[ad_1] Company hosting cPass webinar on Friday, October 22, 2021 for long-term care facilities New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – October 21, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the publication of an article entitle
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
[ad_1] Dr. Jorge Leone, Chief Scientific Officer of Todos Medical, and Sean Taylor, North American FAS Manager of Genscript, will discuss the importance of the cPass™ SARS-COV-2 neutralizing antibody test as a “New Paradigm for Measuring Immunity in a Pre- and Post-Vaccination Era” AMDA’s 5,500 members work in skilled nursing facilities, long-term care and a
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – October 04, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today provided an update on its COVID-19 oral antiviral 3CL protease (“Main Protease”, or “Mpro”) inhibitor Tollovir® clinical development pr
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir
[ad_1] – Treatment group participants experienced a reduction in key inflammatory biomarker – Observed a reduction in time of hospitalization and death rate with no deaths recorded in treatment group New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 30, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQ
Todos Medical Launches Tollovid Daily via Subscription at MyTollovid.com
[ad_1] Consumers can subscribe for an auto-shipped supply of Tollovid Daily™ 3CL protease inhibitor for immune support every month New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 23, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced an ex
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 24, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into an agreement with holders of the Company’s convertible notes that provides for a 90-day moratorium on conversions an
Todos Medical Reports Second Quarter 2021 Financial Results
[ad_1] Company recorded positive earnings of $0.01 per share as financial condition improved New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 24, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced financial results today for the second qua
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid and Tollovid Daily Through Coinbase Commerce
[ad_1] Cryptocurrency accepted include Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Cash (BCH) and Litecoin (LTC) New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 17, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and solutions company with comprehensive product offerings, today announced that it
Todos Medical's CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
[ad_1] · CEO Gerald Commissiong to appear on Yahoo! Finance Live Today at 4:10 pm EDT · Respiratory panel critical as Back to School begins heading into Fall 2021 · RSV and Influenza expected to make resurgence with low masking compliance New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – September 1, 2021 – Todos M
Todos Medical's CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
[ad_1] · Company sees a significant market opportunity for reference lab agreements to identify which variant is responsible for positive COVID-19 test results · Validation paves the way for launch of variant testing at Provista in September 2021 New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – August 26, 2021 – Todos Med
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid(TM)
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – August 5, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has received a notice of allowance from the US Patent & Trademark Office (USPTO) for a trademark for the Company’s proprietary supplement Tol
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid(TM)
[ad_1] New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – August 5, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has received a notice of allowance from the US Patent & Trademark Office (USPTO) for a trademark for the Company’s proprietary supplement Toll
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily Including 3CL Protease Inhibitor Claim
[ad_1] · New twice-a-day dosing regimen allows for daily immune system support · Company intends to create a monthly subscription model for this new product New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – July 22, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company
Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test
[ad_1] · Todos plans to commercialize Videssa in late 2021 to reduce unnecessary biopsies in the $7.19 billion mammogram naïve market and integrate it into its TBIA Platform · Provista Diagnostics’ testing lab in the Atlanta, Georgia area is currently performing COVID-19 testing, that will be automated to significantly increase processing capac
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
[ad_1] NEW YORK, NY, and REHOVAT, ISRAEL – (NewMediaWire) – April 8, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics solutions company, today announced that it has received a notice of allowance (‘Letter of Intent to Grant a Patent’) from the European Patent Office covering the use of the Company’s proprietary
Todos Medical Applauds Senate and House Passage of the American Recovery Act
[ad_1] New York, NY – (NewMediaWire) – March 11, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood tests for early detection of cancer and Alzheimer’s disease, today applauded the Senate
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
[ad_1] · $12.5M in combined January 2021 and February 2021 sales · President Biden signs American Recovery Act into law Rehovot, Israel – (NewMediaWire) – March 12, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and im
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
[ad_1] New York, NY – (NewMediaWire) – December 23, 2020 – Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced that it has entered into a preferred
Todos Medical Provides Strategic Outlook
[ad_1] New York, NY – (NewMediaWire) – December 1, 2020 – Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today provided a corporate update to the market, as we
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
[ad_1] · Todos adds lab plastics, including manual and robotic pipette tips, to its offering · Wisconsin lab client doubled weekly orders to support 50,000 PCR tests per week ahead of expected post-Thanksgiving testing surge Rehovot, Israel – (NewMediaWire) – November 24, 2020 – Todos Medical (OTCQB: TOMDF), an in vitro diagnost
Todos Medical Announces Positive In Vitro Data for Tollovid Confirming 3CL Protease Inhibition Mechanism of Action
[ad_1] Rehovot, Israel – (NewMediaWire) – November 20, 2020 – Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive in vitro data by its join
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
[ad_1] · Tollovid is a proprietary blend of plant extracts administered orally as dietary supplement · The US FDA granted a Certificate of Free Sale for Tollovid on August 28, 2020 · Tollovid ingredients inhibit the 3CL protease, a key protease required for coronavirus replication · The Alchemist’s Kitchen will launch Tollovid in No
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
[ad_1] New York, NY – (NewMediaWire) – October 22, 2020 – Todos Medical (OTCQB:TOMDF) (“Todos”), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, along with Adial Pharmaceuticals, Inc. (N
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
[ad_1] · Received first payments from $47.5 million contract with Wisconsin client on October 9, 2020 · Wisconsin client upped avg. kit purchases from 2,100+/day to 3,500+/day on October 12, 2020 · Todos has completed equipment purchases for signed Q3/20 reagent supply agreements · Existing contracts that have the potential to deliv
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
[ad_1] Rehovot, Israel – (NewMediaWire) – September 25, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
[ad_1] · NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement · US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 · JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel · Todos evaluating commercialization options for NLC-001 Worldwide Rehovot,
Todos Medical CEO Releases Letter to Shareholders
[ad_1] · Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US · 3CL Protease-based saliva test making progress in Israel · 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio · 2019 convertible note holders and institutional Q1/2020 convertible note holders sign tempor
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
[ad_1] New York, NY – (NewMediaWire) – September 16, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has expanded its pa
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
[ad_1] New York, NY – (NewMediaWire) – September 11, 2020 – – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that the U.S. Food and Dr
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
[ad_1] New York, NY – (NewMediaWire) – September 3, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced sales for the month of Augus
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
[ad_1] NEW YORK, NY, REHOVOT, Israel, and SINGAPORE – (NewMediaWire) – August 27, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announce
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
[ad_1] · 6-month contract anticipates demand of 3,000 tests per day · Todos has the right to supply up to 30,000 tests per day if demand increases for the lab Rehovot, Israel – (NewMediaWire) – August 21, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions
UPDATE: Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
[ad_1] – Initial Investment of $275,000 followed by up to $10 Million commitment over 24-months REHOVOT, Israel, SINGAPORE and NEW YORK – (NewMediaWire) – August 10, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and d
Todos Medical Announces July Sales of COVID-19 Tests
[ad_1] · Sales during July exceeded $550,000 NEW YORK, NY REHOVOT, Israel and SINGAPORE – (NewMediaWire) – August 7, 2020 – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of canc